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Abstract
Background: CaM-KIIN has evolved to inhibit stimulated and autonomous activity of the Ca
2+/calmodulin (CaM)-dependent
protein kinase II (CaMKII) efficiently, selectively, and potently (IC50 ,100 nM). The CN class of peptides, derived from the
inhibitory region of CaM-KIIN, provides powerful new tools to study CaMKII functions. The goal of this study was to identify
the residues required for CaMKII inhibition, and to assess if artificial mutations could further improve the potency achieved
during evolution.
Methodology/Principal Findings: First, the minimal region with full inhibitory potency was identified (CN19) by
determining the effect of truncated peptides on CaMKII activity in biochemical assays. Then, individual residues of CN19
were mutated. Most individual Ala substitutions decreased potency of CaMKII inhibition, however, P3A, K13A, and R14A
increased potency. Importantly, this initial Ala scan suggested a specific interaction of the region around R11 with the
CaMKII substrate binding site, which was exploited for further rational mutagenesis to generate an optimized pseudo-
substrate sequence. Indeed, the potency of the optimized peptide CN19o was .250fold improved (IC50 ,0.4 nM), and
CN19o has characteristics of a tight-binding inhibitor. The selectivity for CaMKII versus CaMKI was similarly improved (to
almost 100,000fold for CN19o). A phospho-mimetic S12D mutation decreased potency, indicating potential for regulation
by cellular signaling. Consistent with importance of this residue in inhibition, most other S12 mutations also significantly
decreased potency, however, mutation to V or Q did not.
Conlusions/Significance: These results provide improved research tools for studying CaMKII function, and indicate that
evolution fine-tuned CaM-KIIN not for maximal potency of CaMKII inhibition, but for lower potency that may be optimal for
dynamic regulation of signal transduction.
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Introduction
CaM-KIIN is a natural CaMKII inhibitor protein expressed in
brain [1,2], where CaMKII is also most abundant (constituting up
to 2% of total protein) [3–5]. The detailed physiological functions
of CaMKII inhibition by CaM-KIIN are still unclear. However,
precise regulation of CaMKII activity is known to be required for
controlling forms of synaptic plasticity underlying higher brain
functions such as learning and memory (for review see [6–8]). For
instance, long term potentiation (LTP) of synaptic strength
requires CaMKII activity [9–13]. However, Ca
2+/CaM stimulat-
ed CaMKII activity alone is not sufficient; Ca
2+/CaM-indepen-
dent ‘‘autonomous’’ CaMKII activity (i.e. partial activity even
after dissociation of Ca
2+/CaM) generated by T286 auto-
phosphorylation [14–17] is also required for LTP induction and
learning [18,19]. Interestingly, like LTP, efficiency of T286 auto-
phosphorylation depends on the stimulation frequency [20,21].
Furthermore, additional inhibitory auto-phosphorylation at
T305/306 [22,23] appears to determine if autonomous CaMKII
promotes potentiation or depression of synaptic strength [24] and
is important in flexibility of learning [25]. All of these regulatory
mechanisms also control activity-induced synaptic CaMKII
translocation [26–28] and binding to the NMDA-type glutamate
receptor subunit GluN2B [29–31], a process also important
regulating synaptic strength [32–34]. CaM-KIIN can interfere
with all of these CaMKII regulatory mechanisms: It is competitive
with GluN2B binding [35,36] and efficiently inhibits CaMKII
activity [1,2,35,36] as well as T305/306 auto-phosphorylation
[35]. Somewhat surprisingly, it only mildly reduces T286 auto-
phosphorylation [35], but effectively blocks the resulting autono-
mous activity [1,36]. In contrast to CaMKII, which is enriched at
dendritic spine synapses, CaM-KIIN is restricted to the dendritic
shaft [2], suggesting specific local control of CaMKII regulation.
Expression of CaM-KIIN is upregulated during consolidation of
fear memory [37,38], suggesting that it is indeed involved in fine
tuning CaMKII signaling that mediates higher brain function.
The CaMKII inhibitory region of CaM-KIIN was initially
shown to be contained within a 27 amino acid sequence [1,2],
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corresponding CN inhibitor peptides CN27 (also known as
CaMKIINtide) and CN21 provided important new research tools
[19,34,36,39,40]. They are more selective than the traditional KN
inhibitors of CaMKII [1,35], which additionally inhibit CaMKIV
[41] and voltage gated Ca
2+ and K
+ channels [42,43]. More
importantly, KN inhibitors are competitive with CaM and inhibit
only stimulated but not autonomous activity of CaMKII[36,44,45],
and thus do not allow probing the specific functions of this hallmark
feature of CaMKII regulation. For instance, both KN and CN
inhibitors provide protection from excitotoxicity when applied
during a glutamate insult, but only CN inhibitors could provide
therapeutically relevant post-insult neuroprotection when instead
applied significantly after the insult [36,46]. This implicated
autonomous CaMKII activity as the drug target relevant for post-
insult neuroprotection, a conclusion corroborated by experiments
with the autonomy-incompetent T286A mutant [36].
This study set out to identify the CaM-KIIN residues important
for CaMKII inhibition. CN19 was identified as the minimal region
that contains the full inhibitory potency. Mutational analysis
showed that the region around R11 of CN19 is of special
importance, and that potency of CN19 can be .250fold further
increased. Additionally, the results indicated a potential for
regulation of CaM-KIINa by phosphorylation (at S12 of CN19).
Materials and Methods
Material
CaM and CaMKII was purified after bacterial or baculovirus/
Sf9 cell expression as described [30,47]. Other kinases were
purchased (PKA and PKC from PhosphoSolutions; others from
SignalChem). CN peptides were made by Fmoc synthesis and
analyzed by HPLC and MS/MS (Chi Scientific). All CN peptides
were N-terminally acetylated and C-terminally amidated, except
for the peptides used for the initial Ala scan. Substrate peptides
were purchase from Genescript or as indicated. Chemicals were
obtained from Sigma and Perkin Elmer.
CaMKII activity assays
Standard reactions (1 min at 30uC) were started by adding
CaMKIIa (2.5 nM subunits, unless stated otherwise) to a mix of
50 mM PIPES pH 7.2, 0.1% BSA, 1 mM CaM, 1 mM CaCl2,
10 mM MgCl2, 100 mM[ c-
32P]ATP (,1 Ci/mmole), 75 mM
substrate peptide (syntide 2, or as indicated), and inhibitor peptide
as indicated. Reactions with 0.1 nM CaMKII were done for
10 min.
For all kinase activity assays, reactions were stopped by spotting
onto P81 cation exchange chromatography paper (Whatman)
squares. After extensive washes in water, phosphorylation of the
substrate peptide bound to the P81 paper was measured by the
Cherenkov method.
Activity assays of other kinases
Reactions were performed essentially as described for CaMKII.
However, for AMPK, 100 mM AMP was added to the reaction.
For AMPK, PKC, and PKA, the reaction mix contained 1 mM
EGTA instead of CaCl2 and CaM. Prior to activity assays,
CaMKI (12.5 nM) and CaMKIV (80 nM) were phosphorylated
by CaMKKa (1.25–4 nM) for 5 min at 30uCi nC a
2+/CaM
containing buffer. Additionally, kinase amount, reaction time, and
the substrate (obtained from different companies as indicated) was
varied as follows: 2.5 nM CaMKIa, 3 min, syntide 2 (Genescript);
5 nM CaMKIV, 10 min, CaMK2g 345–358 peptide (Anaspec);
2.5 nM DAPK1 1–363, 3 min, MLC-derived peptide (Anaspec);
5 nM AMPK-a2b1c1, 10 min, SAMStide (SignalChem); 5 nM
PKA, 10 min, Kemptide (Genescript); 2 nM PKC, 10 min,
MARCKS peptide (Anaspec). PKA and PKC were purified from
bovine heart or rat brain, respectively. PKA was catalytic subunits
only (without regulatory R subunits) and PKC was the
constitutively active tryptic PKM fragment; thus, both kinases
did not require stimulation for activity. Other kinases were
recombinant protein from mouse (CaMKI) or human (CaMKK,
CaMKIV, DAPK1, AMPK), of the isoform and/or subunit
composition indicated above.
Circular dichroism
Was done in the UC Denver Biophysics Core using a Jasco J815
Circular Dichroism spectropolarimeter. Peptide concentration was
0.25 mg/ml.
Statistics
All pair-wise comparisons were done using a two-tailed t-test,
using Excel software (Microsoft). Comparisons of multiple
conditions were done by one-way ANOVA with Newman-Keuls
multiple comparison post hoc analysis, using Prism software
(GraphPad).
Results
Full inhibitory potency is retained by CN19 but not by
shorter peptides
Previous studies showed that the 21 mer CN21 (Fig. 1A)
contains the inhibitory region of CaM-KIIN, as it retains full
potency of CaMKII inhibition [35]. Systematic further truncation
of CN21 defined the minimal inhibitory region, CN19 (Fig. 1B).
Truncation of the N-terminus of CN21 by 2 amino acids
completely abolished CaMKII inhibition, and potency was
significantly reduced even by deleting only 1 amino acid.
However, C-terminal truncation by 1 or 2 amino acids did not
affect potency. Only further truncation by 3 amino acids
significantly reduced potency (Fig. 1B). Thus, the peptide C-
terminally truncated by 2 amino acids (now termed CN19)
contains the minimal inhibitory region with full inhibitory
potency. Phosphorylation of syntide 2 by CaMKII was inhibited
by CN21, CN20 and CN19 with an IC50 of ,100 nM (Fig. 1C).
Syntide 2 is a ‘‘regular’’ S-site binding CaMKII substrate [17], and
CN peptides inhibit its phosphorylation in a non-competitive
manner [2]. We additionally tested AC3, an S- and T-site binding
substrate [17], as this T-site binding results in competitive
inhibition by CN peptides, which also bind to the T-site [35].
Note that the only other known T-site binding CaMKII substrate
site is S1303 on the NMDA-type glutamate receptor subunit
GluN2B [30,48]. The series of truncated CN peptides showed the
same principle effect on inhibition of CaMKII activity towards
AC3 as seen with syntide 2 (Fig. S1). However, the IC50 of both
CN21 and CN19 was 10fold higher for AC3 (,1 mM), consistent
with the competition of CN21 with this unusual CaMKII
substrate.
CN19 is unordered in solution
CN peptides and the helical CaMKII auto-inhibitory region
interact with the same site on the CaMKII kinase domain, the T-
site [35]. However, examining CN19 with circular dichroism (for
review and technical considerations see ref. [49]) did not reveal
any helical structure, and instead indicated that CN inhibitory
region is mainly unordered (Fig. S1). Consistent with this result,
sequence based secondary structure prediction [50] also indicated
mainly coiled structure and absence of helical elements (Fig. S2).
Improved CaMKII Inhibitors
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crystal structure of CaMKII-bound CN27 [51]. This difference in
secondary structure to the a-helical CaMKII auto-inhibitory
region [52] may explain why no clear sequence homology between
CN19 and the CaMKII auto-inhibitory region was detectable,
despite their similar interaction site on the core CaMKII kinase
domain.
Ala scan of CN19 reveals 3 mutations that increase
potency
Truncation to a 19 mer enabled efficient small-scale peptide
synthesis in a 96-well format, and thus efficient generation of
CN19 mutation series. In an initial screen, we substituted each
CN19 residue individually for Ala, and tested the effect on
CaMKII inhibition (Fig. 2). As expected, most Ala substitutions
significantly reduced CN19 potency: 6 mutants reduced potency
more than 3fold, and an additional 8 mutants reduced potency to
a lesser extent; only 2 mutants showed no significant effect (Fig. 2).
However, three mutants (P3A, K13A, and R14A) actually
significantly increased potency of CN19 (Fig. 2). CN19 contains
8 charged residues, and we expected that these residues would
contribute most to interaction with and inhibition of CaMKII.
However, the only charge substitution that reduced potency more
than 3fold was R11A, and two of the charge substitutions even
increased potency. Another surprising effect was the .3fold
decrease in potency by the S12A substitution, as the b isoform of
CaM-KIIN contains an Ala in this position, constituting the only
difference between the two isoforms within their inhibitory region
[2]. Taken together, the random Ala scan provided results that
were not predicted by rational or intuition.
S12 is sensitive to mutation, indicating a potential for
regulation by phosphorylation
The CN19 region most sensitive to Ala substitutions (surround-
ing R11) contains a Ser (S12) that could be subject to
phosphorylation. A phospho-mimetic S12D mutation of CN19
Figure 1. CN19 is the minimal CaMKII inhibitory region of CaM-KIINa with full potency. The effect of CN peptides (concentration as
indicated) on activity of CaMKII (20 nM) was tested by in vitro phosphorylation assays of peptide substrates (40 mM syntide 2). A, The sequence of
CN21, which contains the full inhibitory potency of CaM-KIIN [35]. Further truncations tested for CaMKII inhibition are indicated. B, CN21 N-terminal
truncation even by one amino acid DN1) or C-terminal truncation by 3 amino acids (DC3) significantly reduced CaMKII inhibition, while C-terminal
truncation by 2 amino acids (DC2, now termed CN19) did not. C, CN21, CN20 (DC1) and CN19 (DC2) showed the same IC50 (,0.1 mM) for inhibition of
CaMKII activity towards the regular substrate syntide 2. In all panels, error bars indicate s.e.m.; **: CN21, DC1, and DC2 were not different between
each other, but differed from all other conditions (p,0.05).
doi:10.1371/journal.pone.0025245.g001
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indicating that phosphorylation would have a regulatory effect. In
order to prevent such inactivating effect when using CN peptides
as research tools for CaMKII inhibition within cells, it would be
desirable to substitute S12 with a non-phosphorylated residue.
However, S12A caused a similar reduction in CN19 potency as
S12D (Fig. 3). Thus, we tested if alternative substitution of S12 with
other residues may be possible. Indeed, while S12 substitution with
G, P, N, F or L also significantly reduced potency, substitution with
V, R, or Q did not (Fig. S3; see also Table 1 and Fig. 4B).
Combining mutations to further increase CN19 potency
As a next step towards improved CN peptides, we compared
combinations of the three mutations that individually increased
potency of CaMKII inhibition. Indeed, the triple mutant P3A,
K13A, R14A (CN19a3) did significantly further increase potency
compared to single mutant with the highest potency, R14A
(Fig. 4A). However, the largest increase in potency was observed
for the double mutant P3A, R14A (CN19a2) (Fig. 4A).
Importantly, CN19a2 could be combined with S12V (CN19a2v;
to prevent S12phosphorylation) without loss of its potency (Fig. 4B).
Again, potency of CN19a2v was significantly stronger compared to
CN19a3 with additional S12V mutation (CN19a3v)(Fig. 4B). With
an IC50 of ,20 nM (Fig. 4B), the potency of CN19a2v was ,5fold
greater compared to CN19 (see Figs. 1C and 2).
Additional mutant screens yielded alternatives but no
clear improvements
Several additional rounds of mutations (which mainly tested
substitutions in CN19 wt, a2, or a3 with positively charged R or K
Figure 2. Ala scan of CN19 identifies 3 mutations with higher potency and 6 mutations with .3fold reduced potency. CaMKII
phosphorylation of syntide 2 was assessed in vitro in presence of 0.3 and 0.1 mM CN19 mutants, as indicated. Error bars indicate s.e.m.
doi:10.1371/journal.pone.0025245.g002
Figure 3. Phospho-mimetic S12D mutation significantly re-
duced CN19 ability to inhibit CaMKII activity (measured by
syntide 2 phosphorylation in vitro). S12 was sensitive also to
various other mutations (see Table 1 and Fig. S3). Error bars indicate
s.e.m. in all panels.
doi:10.1371/journal.pone.0025245.g003
Improved CaMKII Inhibitors
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25245residues) did not yield any further improvements over CN19a2v.
However, several residues that could be substituted without
reduction in potency were identified (Fig. S4). This included
positions 3 (K), 5 (R), 7 (R,K), 8 (K), and 9 (L). The results,
inferring the effects of all tested substitutions individually, are
summarized in Table 1.
The mutations in CN19a2v slightly increase selectivity for
CaMKII vs. CaMKI
CN inhibitors are highly selective for CaMKII [1,35]. Like
CN27 and CN21, CN19 did not significantly inhibit activity of the
closely related kinase CaMKI at 5 mM( ,50fold the IC50 of
CaMKII inhibition)(Fig. 5A). CN19a2 and CN19a2v also did not
inhibit CaMKI at this concentration (.250fold of their IC50 for
CaMKII)(Fig. 5B). However, at 20 mM, they did reduce CaMKI
activity, while CN19 did not (Fig. 5B). Potency of CaMKI
inhibition was ,2fold greater for CN19a2v (,18 mM IC50)
compared to CN19 (,36 mM IC50)(Fig. S5). However, selectivity
for CaMKII vs CaMKI was still ,2.5fold increased for CN19a2v
(,900fold selectivity) compared to CN19 (,360fold selectivity),
due to the even further increased potency of CaMKII inhibition
(IC50 of ,20 nM for CN19a2v compared to ,100 nM for CN19;
see Figs. 1C, 2 and 4B).
A rational strategy to further improve potency of CN19
The initial Ala scan revealed that R11 is the single most
important charged residue for potency of CaMKII inhibition. As
the minimal consensus sequence for CaMKII substrates is RxxS/
T, we reasoned that R11 might provide the R at the 23 position
for a pseudo-substrate sequence within CN19 that directly blocks
the substrate binding site (Fig. 6A). Thus, we decided to test several
mutations that make the CN19a2v region around R11 more
similar to an optimal CaMKII substrate sequence (without
introducing a phosphorylatable residue)(Fig. 6A): Though less
important than the R at the 23 position, CaMKII prefers
substrates with hydrophobic residues at the 25 and +1 positions
and also shows some preference for substrates with Q at 22, F at
+1 and E or D at +2 positions [53]. Indeed, both V12Q and V16D
significantly increased potency (Fig. 6B). V15I also increased
potency, however, the V15F mutation that was expected to be
optimal in this position did not (Fig. 6B). The V12Q and V16D
mutants of CN19a2v had an IC50 of ,1 nM, and a combination
mutant (now termed CN19o) increased potency even further
(Fig. 6C). 5 nM CN19o blocked CaMKII activity almost
completely (Fig. S6). Additional combination of CN19o with
V15I or V15F did not further increase potency (Fig. 6C).
The optimized CN19o has both increased potency and
selectivity
CN19o inhibited CaMKII with an IC50 of ,0.4 nM (Fig. 7A),
and thus has .250fold enhanced potency compared to CN19. If
any, this result underestimates the potency of CN19o: Even though
concentration of CaMKII in this assay was significantly reduced
compared to standard assays (to 0.1 nM), the inhibitor excess at the
determined IC50 was only 4fold. Indeed, the determined IC50
value was dependent on the CaMKII concentration in the assays
Table 1. CN19, CN19o, CN19a2V and effects of the individual
CN19 mutations on CaMKII inhibition in summary.
CN19 o a2v + , -
1K A R
2R A
3P AAA,K.R
4P AK
5K R A R
6L A
7G R K R
8Q AK R
9I L A R
10 G A
11 R A
12 S QVQ* VR A KD
GPNFL
13 K A
14 R AAA
15 V (I)* AR(F)*
16 V D D* A R
17 I ARK
18 E AR
19 D AR C
Asterisks indicate the rational mutagenesis.
doi:10.1371/journal.pone.0025245.t001
Figure 4. CN19a2v is a further improved combination mutant.
Effect of CN19 peptides (20 nM) on CaMKII activity towards syntide 2 in
vitro. A, CN19a2 (P3A, R14A) was the most potent double mutant of
CN19, and also more potent that the triple mutant CN19a3 (P3A, K13A,
R14A)(**, p,0.01). B, S12V mutation of CN19a2 (CN19a2v) did not
reduce potency, and was more potent than a S12V mutant of CN19a3
(***, no difference between a2 and a2v, but p,0.001 compared to the
other conditions). Error bars indicate s.e.m. in all panels.
doi:10.1371/journal.pone.0025245.g004
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binding inhibitor’’ [54].
As CN19a2v increased potency not only for CaMKII but also
for CaMKI inhibition, we tested if the optimized CN19o also
shows such undesired correlation. On the contrary, potency of
CaMKI inhibition by CN19o (,38 mM IC50) was reduced
compared to CN19a2v (,18 mM IC50), and instead similar to
CN19 (,36 mM IC50)(Fig. S5). Thus, the resulting selectivity of
CN19o for CaMKII vs CaMKI is almost 100,000fold (and
.250fold greater compared to CN19).
Additionally, CN19o was tested for effects on a panel of other
kinases (Fig. 7B). This panel included other CaM kinase family
members (CaMKIV, DAPK1, AMPK) and other basophilic
multifunctional kinases (PKA, PKC). Even at 5 mM( .10,000fold
IC50 for CaMKII), CN19o did not significantly affect activity of
these other kinases tested. Thus, CN19o inhibits CaMKII both
with remarkable potency and high selectivity.
Discussion
Fine tuning of CaMKII activity and localization by a complex
set of regulatory mechanisms is required for neuronal plasticity
underlying higher brain functions. Here, we identified and
characterized the minimal inhibitory region (CN19) of the
neuronal CaMKII-regulatory protein CaM-KIINa. The region
around R11 of CN19 was especially important for potency of
CaMKII inhibition. S12 was sensitive to substitutions with most
other residues, including phosphomimetic S12D mutation,
indicating a possible mechanism for dynamic regulation by
phosphorylation in response to neuronal stimulation. Remarkably,
by combining random and rational mutation strategies, it was
possible to increase CN19 potency .250fold, thereby generating a
much improved tool (CN19o) for studying CaMKII functions.
With an IC50 of ,0.4 nM, the dose required for efficient
inhibition is no longer limited by the concentration of CN19o, but
by the amount of CaMKII.
CN19 is the minimal inhibitory region of CaM-KIINa with full
potency, as CaMKII inhibition was significantly reduced only by
further truncation. CN19 consists of over 40% charged residues,
which appeared to indicate that inhibition involves strong
electrostatic interaction. However, only substitution of R11
decreased potency by .3fold, while substitution of K13 and
R14 even increased potency. By contrast, substituting any of the
three long hydrophobic residues decreased potency, two of them
(L6 and I9) by .3fold. Overall, the region around R11 (i.e. I9-
S12) contributed most to CaMKII inhibition, indicating that R11
may constitute the 23 position R in a pseudo-substrate
interaction. Indeed, by far the greatest increase in CN19 potency
Figure 5. CaMKI inhibition is enhanced by the CN19a2 and a2v
mutations, but to a lesser extent than CaMKII inhibition, thus
slightly enhancing selectivity for CaMKII vs CaMKI. Effects of
CN19 peptides on activity of the closely related CaM kinase CaMKI was
assessed in vitro. A, Like CN27 and CN21, CN19 did not affect CaMKI
activity at 5 mM (50fold IC50 for CaMKII), as there was no statistical
difference between the conditions (ANOVA). B, Like CN19, CN19a2 and
a2v did not affect CaMKI activity at 5 mM( .250fold their IC50 for
CaMKII). However, unlike CN19, they did significantly reduce CaMKI
activity (to ,60%) at 20 mM( .1,000fold their IC50 for CaMKII)
(**, p,0.05).
doi:10.1371/journal.pone.0025245.g005
Figure 6. Rational mutagenesis dramatically improved potency
in the optimized CN19o. A, Sequence alignment illustrates the
rationale for further mutagenesis. The initial Ala scan (Fig. 2) indicated
that R11 of CN19 may constitute the 23 position R of a pseudo-
substrate sequence. B, The CN19a2v mutations V12Q, V15I and V16D
dramatically increase CaMKII inhibition. C, The optimal combination
mutant of CN19a2v was V12Q, V16D (CN19o). Additional V15F mutation
did not further increase inhibition of CaMKII (0.5 nM), and all other
combination mutants showed less CaMKII inhibition (**, p,0.05). Error
bars indicate s.e.m. in all panels.
doi:10.1371/journal.pone.0025245.g006
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substrate sequence around R11: The optimized CN19o had
.250fold increased potency. Selectivity of CaMKII vs CaMKI
inhibition was similarly increased, and is almost 100,000fold for
CN19o. High selectivity for CaMKII was further corroborated by
lack of CN19o effects on a panel of other related kinases (CaMKI,
CaMKIV, DAPK1, AMPK, PKA, and PKC), even at 5 mM
(.10,00fold IC50 for CaMKII).
A recent crystal structure of CaMKII-bound CN21 [51]
supports several of our conclusions, including the sufficiency of
CN19 for full inhibitory potency, the pseudo-substrate interaction
of R11 in CN19 (R52 in CaMK-IIN) and the strong contribution
of I9 and L6 to the binding. Other residues implicated by the
structure, such as V15, K5, and especially R2 [51], did not
contribute as strongly to the IC50 in our biochemical studies.
More careful examination of the structure also suggests a specific
electrostatic interaction of R14 with D156 of the CaMKII kinase
domain. However, an R14A mutation was found here to instead
significantly increase potency of inhibition. The reasons for this
effect is currently unclear, but it may indicate that disturbing the
original R14 interaction may allow formation of other interactions
that are able to support binding and/or inhibition more strongly.
Enhancement of CN19 potency by the other mutations identified
here is consistent with the crystal structure, but could not have
been directly predicted by it.
If CaMKII inhibition by CN peptides involves a pseudo-substrate
interaction, why is the inhibitory mechanism non-competitive with
regular substrates [2]? The answer may lie in a non-equilibrium
competition, in which CN peptides can displace substrate from the
substrate binding S-site, but substrate cannot displace CN peptides,
possibly due to the additional interaction of CN peptides with the
CaMKII T-site [36]. Indeed, inhibition by CN peptides is
competitive with unusual substrates that can bind also to the T-site
in addition to the S-site [35]. Furthermore, while initiating CaMKII
binding to both substrate and to CaM-KIINa requires a Ca
2+/CaM
stimulus, dissociation of CaM reverses only binding to regular
substrates but not to CaM-KIINa [2], GluN2B [30,55], or connexin
36 [56], the only known exogenous T-site interacting proteins.
A database search (protein blast) revealed that CaM-KIIN
homologues are found in mammals, birds, frogs, and fish. At first
glance, it seems unlikely that one could significantly improve on
.300 M years of evolution in the laboratory. Upon more careful
consideration, this is much dependent on how one defines
‘‘improvement’’. Obviously, it was possible to dramatically
enhance potency of CN19. Thus, evolution has fine tuned CaM-
KIIN not for maximal potency of CaMKII inhibition, but for a
lower potency that may be sufficient for effective CaMKII
inhibition and may additionally allow better dynamic control of
CaMKII activity. Indeed, the inhibitory region of CaM-KIINb is
identical from zebra fish to humans, indicating evolutionary
pressure also against mutations that further increase potency of
CaMKII inhibition. The inhibitory region of CaM-KIINa (CN19)
may have appeared later in evolution, and is identical in mammals
and birds. The only difference to the inhibitory regions of CaM-
KIINb is a single Ala to Ser substitution (S12 in CN19). This
generates the potential for dynamic control directly regulated by
cellular signaling, as our results indicate that S12 phosphorylation
would interfere with CaMKII inhibition. The only other known
mechanism to regulate CaM-KIIN is control of its expression,
which indeed occurs in response to learning [37,38]. Phosphor-
ylation can provide control with higher temporal accuracy and
resolution. Thus, it will be interesting to see if CaM-KIIN can be
phosphorylated in response to cellular stimulation. The high
content of basic residues in CN19 (.30%) may indicate
phosphorylation by a basophilic kinase. However, basophilic
kinases such as CaMKII, PKA, and PKC prefer Arg in the 23o r
22 position, and CN19 contains an Arg instead at the 21 position
of S12. Thus, it is currently unclear which of the ,400 Ser/Thr
protein kinases [57] may be able to mediate S12 phosphorylation.
Most mutations of S12 significantly decreased potency of CaMKII
inhibition. However, of importance for developing an optimized
research tool for studying CaMKII function, S12Q mutation
instead enhanced inhibitory potency.
Clearly, CaM-KIIN can participate in the fine tuning of the
CaMKII activity required for regulation of synaptic plasticity that
underlies higher brain function. Additionally, CaM-KIIN may
curb over-activation of CaMKII in pathological glutamate
signaling that causes neuronal damage after stroke. Indeed, CN
peptides were neuroprotective even when applied after glutamate
insults in culture [36,46] or a stroke model in mouse [36].
However, the physiological and pathological consequences of
CaMKII control by endogenous CaM-KIIN remain to be
elucidated. The results of this study provide a further improved
research tool for studying CaMKII functions. Indeed, a cell
penetrating version of the ‘‘intermediately improved’’ CN19a2v
has already been used successfully to examine CaMKII functions
in hippocampal slice preparations [34], and the decrease in
concentration required for inhibiting CaMKII function corre-
sponded directly to the increase in potency shown here.
Figure 7. Increased potency and selectivity of CN19o. A, The
IC50 for CaMKII inhibition by CN19o is ,0.4 nM, as indicated by CaMKII
activity assays. CaMKII concentration was varied as indicated. B, While
5 nM CN19o completely blocked CaMKII activity, even 5 mM CN19o
(.10,00fold IC50 of CaMKII inhibition) did not significantly affect kinase
activity of CaMKI, CaMKIV, DAPK1, AMPK, PKA, or PKC. Error bars
indicate s.e.m. in all panels.
doi:10.1371/journal.pone.0025245.g007
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Figure S1 CN19 is the minimal CaMKII inhibitory
region of CaM-KIINa with full potency. CN21 and CN19
(DC2) showed the same IC50 (,1 mM) for inhibition of CaMKII
activity towards the T-site binding substrate AC2 (40 mM); further
truncation at the C-terminus or any truncation at the N-terminus
significantly reduced CaMKII inhibition (p,0.001).
(TIF)
Figure S2 CN19 peptides are largely unordered. A,
Circular dichroism indicated that CN19 (0.25 mg/ml) is largely
unordered; no significant content of a-helix of b-sheet structure
was detected (for review and technical considerations of circular
dichroism see ref. [44]). B, Secondary structure prediction (using
NetSurfP, freely available on the website of the Technical
University of Denmark; see ref. [50]) was consistent with mainly
unordered structure of the CN peptides. By contrast, for the
CaMKII autoregulatory region, mainly a-helical structure was
predicted, consistent with its conformation found in a crystal
structure of the kinase subunit [52]. The peptides are aligned
based on the 23 position of a pseudosubstrate sequence (R, in
bold) predicted by further mutational analysis of CN19 (see
Fig. 6A).
(TIF)
Figure S3 Effects of S12 mutations in CN19a3 and a2 on
CaMKII inhibition. A, The CN19a3 S12R mutation retained
potency of CaMKII inhibition, but the S12A, G, P, or N
mutations did not. B, The CN19a2 S12V mutation retained
potency of CaMKII inhibition, but the S12F, L, or K mutations
did not. Error bars indicate s.e.m. in all panels.
(TIF)
Figure S4 Effects of further CN19a3 and a2 mutations
on CaMKII inhibition. A, The CN19a3 mutations K5R, G7R
and I9L retained potency of CaMKII inhibition, but the mutations
K1R, L6R, Q8R or I9R did not. The A3R mutation also lowered
CaMKII inhibition of CN19a3, however, this R mutation still
increased potency compared to the original P3 in CN19. B, The
CN19a2 mutations G7K and Q8R retained potency of CaMKII
inhibition. So did the combination mutant 3,5,7,12R, but
subsequent additional mutations D19A, I17R, and D19R reduced
CaMKII inhibition. Error bars indicate s.e.m. in all panels.
(TIF)
Figure S5 CN19, CN19a2v, and CN19o inhibit CaMKI,
but with 360–100,000fold less potency compared to
CaMKII. The IC50 for CaMKI inhibition of CN19 (36 mM),
CN19a2v (18 mM) and CN19o (38 mM) 360–100,000fold greater
than their IC50 for CaMKII inhibition (100 nM, 20 nM and
0.4 nM, respectively; compare Figs. 1, 4 and 7). For curve fit, the
Hill coefficient was set as 1.
(PDF)
Figure S6 5 nM CN19o blocked CaMKII activity almost
completely, while the same concentration of CN19a2v only
mildly reduced CaMKII acitiviy (to ,75%) and CN19a2v V15I
left some residual CaMKII activity (,10%). Error bars indicate
s.e.m.
(TIF)
Acknowledgments
We thank Ms. Jacqueline Kulbe for excellent technical assistance.
Author Contributions
Conceived and designed the experiments: SC KB. Performed the
experiments: SC KB. Analyzed the data: SC KB. Wrote the paper: KB.
References
1. Chang BH, Mukherji S, Soderling TR (1998) Characterization of a calmodulin
kinase II inhibitor protein in brain. Proc Natl Acad Sci U S A 95:
10890–10895.
2. Chang BH, Mukherji S, Soderling TR (2001) Calcium/calmodulin-dependent
protein kinase II inhibitor protein: localization of isoforms in rat brain.
Neuroscience 102: 767–777.
3. Erondu NE, Kennedy MB (1985) Regional distribution of type II Ca2+/
calmodulin-dependent protein kinase in rat brain. J Neurosci 5: 3270–3277.
4. Tobimatsu T, Fujisawa H (1989) Tissue-specific expression of four types of rat
calmodulin-dependent protein kinase II mRNAs. J Biol Chem 264:
17907–17912.
5. Bayer KU, Lohler J, Schulman H, Harbers K (1999) Developmental expression
of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are
the early isoforms and most abundant in the developing nervous system. Brain
Res Mol Brain Res 70: 147–154.
6. Lisman J, Schulman H, Cline H (2002) The molecular basis of CaMKII function
in synaptic and behavioural memory. Nat Rev Neurosci 3: 175–190.
7. Hudmon A, Schulman H (2002) Neuronal CA2+/calmodulin-dependent
protein kinase II: the role of structure and autoregulation in cellular function.
Annu Rev Biochem 71: 473–510.
8. Lee YS, Silva AJ (2009) The molecular and cellular biology of enhanced
cognition. Nat Rev Neurosci 10: 126–140.
9. Malinow R, Schulman H, Tsien RW (1989) Inhibition of postsynaptic PKC or
CaMKII blocks induction but not expression of LTP. Science 245: 862–866.
10. Silva AJ, Stevens CF, Tonegawa S, Wang Y (1992) Deficient hippocampal long-
term potentiation in alpha-calcium-calmodulin kinase II mutant mice. Science
257: 201–206.
11. Derkach V, Barria A, Soderling TR (1999) Ca2+/calmodulin-kinase II enhances
channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nate type glutamate receptors. Proc Natl Acad Sci U S A 96: 3269–3274.
12. Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, et al. (2000) Driving
AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1
and PDZ domain interaction. Science 287: 2262–2267.
13. Opazo P, Labrecque S, Tigaret CM, Frouin A, Wiseman PW, et al. (2010)
CaMKII Triggers the Diffusional Trapping of Surface AMPARs through
Phosphorylation of Stargazin. Neuron 67: 239–252.
14. Miller SG, Kennedy MB (1986) Regulation of brain type II Ca2+/calmodulin-
dependent protein kinase by autophosphorylation: a Ca2+-triggered molecular
switch. Cell 44: 861–870.
15. Lou LL, Lloyd SJ, Schulman H (1986) Activation of the multifunctional Ca2+/
calmodulin-dependent protein kinase by autophosphorylation: ATP modulates
production of an autonomous enzyme. Proc Natl Acad Sci U S A 83:
9497–9501.
16. Schworer CM, Colbran RJ, Soderling TR (1986) Reversible generation of a
Ca2+-independent form of Ca2+(calmodulin)-dependent protein kinase II by an
autophosphorylation mechanism. J Biol Chem 261: 8581–8584.
17. Coultrap SJ, Buard I, Kulbe JR, Dell’Acqua ML, Bayer KU (2010) CaMKII
autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin.
J Biol Chem 285: 17930–17937.
18. Giese KP, Fedorov NB, Filipkowski RK, Silva AJ (1998) Autophosphorylation at
Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science
279: 870–873.
19. Buard I, Coultrap SJ, Freund RK, Lee YS, Dell’Acqua ML, et al. (2010)
CaMKII ‘‘autonomy’’ is required for initiating but not for maintaining neuronal
long-term information storage. J Neurosci 30: 8214–8220.
20. De Koninck P, Schulman H (1998) Sensitivity of CaM kinase II to the frequency
of Ca2+ oscillations. Science 279: 227–230.
21. Bayer KU, De Koninck P, Schulman H (2002) Alternative splicing modulates
the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J
21: 3590–3597.
22. Colbran RJ (1993) Inactivation of Ca2+/calmodulin-dependent protein kinase II
by basal autophosphorylation. J Biol Chem 268: 7163–7170.
23. Hanson PI, Schulman H (1992) Inhibitory autophosphorylation of multifunc-
tional Ca2+/calmodulin-dependent protein kinase analyzed by site-directed
mutagenesis. J Biol Chem 267: 17216–17224.
24. Pi HJ, Otmakhov N, Lemelin D, De Koninck P, Lisman J (2010) Autonomous
CaMKII can promote either long-term potentiation or long-term depression,
depending on the state of T305/T306 phosphorylation. J Neurosci 30:
8704–8709.
25. Elgersma Y, Fedorov NB, Ikonen S, Choi ES, Elgersma M, et al. (2002)
Inhibitory Autophosphorylation of CaMKII Controls PSD Association,
Plasticity, and Learning. Neuron 36: 493–505.
Improved CaMKII Inhibitors
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e2524526. Shen K, Meyer T (1999) Dynamic control of CaMKII translocation and
localization in hippocampal neurons by NMDA receptor stimulation. Science
284: 162–166.
27. Shen K, Teruel MN, Connor JH, Shenolikar S, Meyer T (2000) Molecular
memory by reversible translocation of calcium/calmodulin-dependent protein
kinase II. Nat Neurosci 3: 881–886.
28. Otmakhov N, Tao-Cheng JH, Carpenter S, Asrican B, Dosemeci A, et al. (2004)
Persistent accumulation of calcium/calmodulin-dependent protein kinase II in
dendritic spines after induction of NMDA receptor-dependent chemical long-
term potentiation. J Neurosci 24: 9324–9331.
29. Strack S, Colbran RJ (1998) Autophosphorylation-dependent targeting of
calcium/calmodulin-dependent protein kinase II by the NR2B subunit of the N-
methyl- D-aspartate receptor. J Biol Chem 273: 20689–20692.
30. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H (2001)
Interaction with the NMDA receptor locks CaMKII in an active conformation.
Nature 411: 801–805.
31. Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, et al. (2002) Regulation
of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-
aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem 277:
48441–48448.
32. Barria A, Malinow R (2005) NMDA receptor subunit composition controls
synaptic plasticity by regulating binding to CaMKII. Neuron 48: 289–301.
33. Zhou Y, Takahashi E, Li W, Halt A, Wiltgen B, et al. (2007) Interactions
between the NR2B receptor and CaMKII modulate synaptic plasticity and
spatial learning. J Neurosci 27: 13843–13853.
34. Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, et al.
(2011) Role of the CaMKII/NMDA Receptor Complex in the Maintenance of
Synaptic Strength. J Neurosci 31: 9170–9178.
35. Vest RS, Davies KD, O’Leary H, Port JD, Bayer KU (2007) Dual Mechanism of
a Natural CaMKII Inhibitor. Mol Biol Cell 18: 5024–5033.
36. Vest RS, O’Leary H, Coultrap SJ, Kindy MS, Bayer KU (2010) Effective post-
insult neuroprotection by a novel Ca(2+)/calmodulin-dependent protein kinase
II (CaMKII) inhibitor. J Biol Chem 285: 20675–20682.
37. Lepicard EM, Mizuno K, Antunes-Martins A, Von Hertzen LSJ, Giese KP
(2006) An endogenous inhibitor of calcium/calmodulin-dependent kinase II is
up-regulated during consolidation of fear memory. European Journal of
Neuroscience 23: 3063–3070.
38. Radwanska K, Tudor-Jones AA, Mizuno K, Pereira GS, Lucchesi W, et al.
(2010) Differential regulation of CaMKII inhibitor beta protein expression after
exposure to a novel context and during contextual fear memory formation.
Genes, Brain and Behavior 9: 648–657.
39. Fink CC, Bayer KU, Myers JW, Ferrell JE, Schulman H, et al. (2003) Selective
regulation of neurite extension and synapse formation by the beta but not the
alpha isoform of CaMKII. Neuron 39: 283–297.
40. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, et al. (2003) Calcium/
calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-
stimulated ERK activation. J Biol Chem.
41. Enslen H, Sun P, Brickey D, Soderling SH, Klamo E, et al. (1994)
Characterization of Ca2+/calmodulin-dependent protein kinase IV. Role in
transcriptional regulation. J Biol Chem 269: 15520–15527.
42. Ledoux J, Chartier D, Leblanc N (1999) Inhibitors of calmodulin-dependent
protein kinase are nonspecific blockers of voltage-dependent K+ channels in
vascular myocytes. J Pharmacol Exp Ther 290: 1165–1174.
43. Li G, Hidaka H, Wollheim CB (1992) Inhibition of voltage-gated Ca2+ channels
and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein
kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-
type Ca2+ channels. Mol Pharmacol 42: 489–488.
44. Tokumitsu H, Chijiwa T, Hagiwara M, Mizutani A, Terasawa M, et al. (1990)
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiper-
azi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
J Biol Chem 265: 4315–4320.
45. Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, et al. (1991) The newly
synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor
KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res
Commun 181: 968–975.
46. Ashpole NM, Hudmon A (2011) Excitotoxic neuroprotection and vulnerability
with CaMKII inhibition. Molecular and Cellular Neuroscience 46: 720–730.
47. Singla SI, Hudmon A, Goldberg JM, Smith JL, Schulman H (2001) Molecular
characterization of calmodulin trapping by calcium/calmodulin-dependent
protein kinase II. J Biol Chem 276: 29353–29360.
48. Omkumar RV, Kiely MJ, Rosenstein AJ, Min KT, Kennedy MB (1996)
Identification of a phosphorylation site for calcium/calmodulindependent
protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor.
J Biol Chem 271: 31670–31678.
49. Greenfield NJ (2007) Analysis of the kinetics of folding of proteins and peptides
using circular dichroism. Nat Protocols 1: 2891–2899.
50. Petersen B, Petersen T, Andersen P, Nielsen M, Lundegaard C (2009) A generic
method for assignment of reliability scores applied to solvent accessibility
predictions. BMC Structural Biology 9: 51.
51. Chao LH, Pellicena P, Deindl S, Barclay LA, Schulman H, et al. (2010)
Intersubunit capture of regulatory segments is a component of cooperative
CaMKII activation. Nat Struct Mol Biol 17: 264–272.
52. Rosenberg OS, Deindl S, Sung RJ, Nairn AC, Kuriyan J (2005) Structure of the
autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme.
Cell 123: 849–860.
53. Songyang Z, Lu K, Kwon Y, Tsai L, Filhol O, Cochet C, et al. (1996) A
structural basis for substrate specificities of protein Ser/Thr kinases: primary
sequence preference of casein kinases I and II, NIMA, phosphorylase kinase,
calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol 16:
6486–6493.
54. Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalysed
reactions by tight-binding inhibitors. Biochim Biophys Acta 185: 269–286.
55. Bayer KU, LeBel E, McDonald GL, O’Leary H, Schulman H, et al. (2006)
Transition from reversible to persistent binding of CaMKII to postsynaptic sites
and NR2B. J Neurosci 26: 1164–1174.
56. Alev C, Urschel S, Sonntag S, Zoidl G, Fort AG, et al. (2008) The neuronal
connexin36 interacts with and is phosphorylated by CaMKII in a way similar to
CaMKII interaction with glutamate receptors. Proc Natl Acad Sci U S A 105:
20964–20969.
57. Manning G, Whyte DB, Martinez R, Hunter R, Sudarsanam S (2002) The
Protein Kinase Complement of the Human Genome. Science 298: 1912–1934.
Improved CaMKII Inhibitors
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e25245